Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways

BackgroundImmune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and pr...

Full description

Bibliographic Details
Main Authors: Vincenzo Quagliariello, Margherita Passariello, Annabella Di Mauro, Ciro Cipullo, Andrea Paccone, Antonio Barbieri, Giuseppe Palma, Antonio Luciano, Simona Buccolo, Irma Bisceglia, Maria Laura Canale, Giuseppina Gallucci, Alessandro Inno, Claudia De Lorenzo, Nicola Maurea
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
immunotherapy
biomarkers
preclinical study
mechanisms
inflammation
interleukin
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.930797/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.930797/full

Similar Items